Drugs / A-079
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05935280 | Jul → Sep 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05249387 | Feb → May 2022 | — | Aalborg University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-079 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3697701 ↗ |
| Known as | A-967079 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249387 ↗ |
| Action | Inhibit | “TRPA1 antagonist” NCT05249387 ↗ |
| Modality | Small molecule | — CHEMBL3697701 ↗ |
| Route | Subcutaneous | “subcutaneous injection of 0.1ml” NCT05249387 ↗ |
| Target | TRPA1 | “TRPA1 antagonist” NCT05249387 ↗ |